×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACIU – ac immune sa (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACIU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
07:00 am
aciu
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
High
Report
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
3/19
04:52 am
aciu
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
High
Report
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
3/16
08:03 am
aciu
AC Immune (ACIU) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
Low
Report
AC Immune (ACIU) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
3/13
01:01 pm
aciu
AC Immune (ACIU) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
AC Immune (ACIU) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/13
07:17 am
aciu
AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M [Seeking Alpha]
Low
Report
AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M [Seeking Alpha]
3/13
07:16 am
aciu
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/13
07:00 am
aciu
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
Medium
Report
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
3/5
07:41 am
aciu
AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD™ 2026 [Yahoo! Finance]
Medium
Report
AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD™ 2026 [Yahoo! Finance]
Date
Time
Symbol
Headline
Impact
3/20
11:59 am
aciu
Form 3 AC Immune SA For: Mar 20 Filed by: Donati Piergiorgio
Medium
Report
Form 3 AC Immune SA For: Mar 20 Filed by: Donati Piergiorgio
3/18
01:09 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: Roberts Christopher James
Medium
Report
Form 3 AC Immune SA For: Mar 18 Filed by: Roberts Christopher James
3/18
12:36 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: Buetler Monika
Low
Report
Form 3 AC Immune SA For: Mar 18 Filed by: Buetler Monika
3/18
12:34 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: Twyman Roy Ervin
Low
Report
Form 3 AC Immune SA For: Mar 18 Filed by: Twyman Roy Ervin
3/18
12:30 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: AGUIAR-LUCANDER RENEE
Low
Report
Form 3 AC Immune SA For: Mar 18 Filed by: AGUIAR-LUCANDER RENEE
3/18
12:20 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: June Carl Howard
Low
Report
Form 3 AC Immune SA For: Mar 18 Filed by: June Carl Howard
3/18
12:20 pm
aciu
Form 3 AC Immune SA For: Mar 18 Filed by: Pfeifer Andrea
Low
Report
Form 3 AC Immune SA For: Mar 18 Filed by: Pfeifer Andrea
3/13
07:02 am
aciu
Form 6-K AC Immune SA For: Mar 13
Medium
Report
Form 6-K AC Immune SA For: Mar 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
AC Immune Q3 2019 Financial Results and Business Update
16.6%
3/30 Form 20-F AC Immune SA For: Dec 31 15.1%
3/23 Form 6-K AC Immune SA For: Mar 23 14.5%
6/11 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 11.2%
3/25 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 9.4%
10/21 Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation 8.6%
4/2 AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases 6.8%
11/19 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.8%
7/17 AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease 5.6%
11/20 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 4.7%
3/30 Form 20-F AC Immune SA For: Dec 31 15.1%
3/23 Form 6-K AC Immune SA For: Mar 23 14.5%
6/11 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 11.2%
3/25 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 9.4%
10/21 Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation 8.6%
4/2 AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases 6.8%
11/19 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.8%
7/17 AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease 5.6%
11/20 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 4.7%
TOP News Decliners
3/26
AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
-30.1%
8/14 Form 6-K AC Immune SA For: Aug 14 -16.8%
3/14 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -9.0%
2/24 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
4/27 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -7.0%
9/26 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.6%
6/28 Form 6-K AC Immune SA For: Jun 28 -6.1%
3/5 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -5.2%
8/12 AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases -4.0%
2/10 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -3.8%
8/14 Form 6-K AC Immune SA For: Aug 14 -16.8%
3/14 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -9.0%
2/24 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
4/27 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -7.0%
9/26 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.6%
6/28 Form 6-K AC Immune SA For: Jun 28 -6.1%
3/5 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -5.2%
8/12 AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases -4.0%
2/10 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: